Journal
ARTHRITIS CARE & RESEARCH
Volume 64, Issue 4, Pages 597-606Publisher
WILEY-BLACKWELL
DOI: 10.1002/acr.21595
Keywords
-
Categories
Funding
- Pfizer Inc.
- Aventis
- Cephalon
- GlaxoSmithKline
- Merck
- Neurocrine
- Pfizer
- Sanofi-Aventis
- Schering-Plough
- Sepracor
- Somaxon
- Somnus
- Syrex
- Takeda
- TransOral
- Ventus
- Wyeth
- XenoPort
- Actelion
- Arena
- Cephalon, Evotec
- Fisher Paykel
- Lilly
- Neurim
- Neurogen
- Organon
- Respironics
- Transcept
- Vanda
- Jazz Pharmaceuticals
Ask authors/readers for more resources
Objective. To assess the effect of pregabalin on polysomnographic (PSG) measures of sleep and patient-rated sleep, tiredness, and pain in fibromyalgia patients. Methods. We performed a randomized, double-blind, placebo-controlled, 2-period crossover PSG study. Patients ages >= 18 years with fibromyalgia satisfied subjective and objective sleep disturbance criteria prior to randomization. Eligible patients were randomized (1: 1) to pregabalin (300-450 mg/day) or placebo for crossover period 1, and vice versa for period 2. Each crossover period comprised a dose-adjustment and dose-maintenance phase, with a 2-week taper/washout between periods. In-laboratory PSGs were recorded during 2 consecutive nights at screening and at the end of each crossover period. The primary end point was the difference in sleep maintenance defined by PSG-recorded wake after sleep onset (WASO; minutes) between 4 weeks of treatment with pregabalin and with placebo. Other PSG measures; patient-rated sleep, tiredness, and pain; and tolerability were assessed. Results. Of 119 patients randomized (103 women [86.6%], mean age 48.4 years), 102 (85.7%) completed both periods. Patients treated with pregabalin showed a reduction in PSG-determined WASO versus treatment with placebo (week 4 difference: -19.2 minutes [95% confidence interval (95% CI) -26.7, -11.6]; P < 0.0001). Pain score improved (decreased) with pregabalin versus placebo treatment at all 4 weeks (week 4 difference: -0.52 [95% CI -0.90, -0.14]; P = 0.0084). Modest (rho = < 0.3) but significant correlations were found between PSG sleep assessments and ratings of pain and sleep quality. Frequently reported all-causality adverse events (pregabalin versus placebo) were: dizziness (30.4% versus 9.9%), somnolence (20.5% versus 4.5%), and headache (8.9% versus 8.1%). Conclusion. Patients with fibromyalgia treated with pregabalin had statistically significant and meaningful improvements in sleep, as assessed by PSG. Patients with fibromyalgia also reported decreased daily pain. Pregabalin was well tolerated.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available